Accelerated Phase Myeloproliferative Neoplasm
Oncology
Prevalence
5.0 / 100K
1 drug in development·1 company·2 clinical trials
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| Pacritinib | Merus N.V. (MRUS) |
Frequently asked questions
How many drugs are in development for Accelerated Phase Myeloproliferative Neoplasm?
BioSniper tracks 1 drug in development for Accelerated Phase Myeloproliferative Neoplasm across 1 company.
How many clinical trials target Accelerated Phase Myeloproliferative Neoplasm?
There are 2 clinical trials targeting Accelerated Phase Myeloproliferative Neoplasm tracked by BioSniper.
What is the prevalence of Accelerated Phase Myeloproliferative Neoplasm?
The estimated prevalence of Accelerated Phase Myeloproliferative Neoplasm is approximately 5.0 per 100,000 population.
Deep-dive into Accelerated Phase Myeloproliferative Neoplasm
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis